Companies /Healthcare
Insmed Inc
NASDAQ: INSM Biotechnology
$101.74
▼ $3.49 (−3.32%) today
Markets closed · 5:22pm ET

Insmed (INSM) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
33%
EPS beat rate
+3.56%
Avg. EPS surprise
Consecutive EPS beats
INSM vs Market · 30-day return after each reportINSMS&P 500
0%+20%+40%+38.6%+6.7%Q1 25+34.7%+2.9%Q2 25+6.4%+0.3%Q3 25−10.6%−4.3%Q4 25−5.7%+0.8%Q1 26−5.8%−0.3%Q2 26
0%+20%+40%Q1 25Q3 25Q1 26
INSM EPS Trend · estimate vs actualEstimateActual
$-1.80$-1.20$-0.60$-1.36$-1.42Q1 25$-1.31$-1.70Q2 25$-1.37$-1.75Q3 25$-1.17$-1.54Q4 25$-1.00$-0.76Q1 26$-0.68$-0.06Q2 26
$-1.80$-1.20$-0.60Q1 25Q3 25Q1 26
INSM Revenue Trend · estimate vs actualEstimateActual
$0$200.0M$400.0M$92.1M$92.8MQ1 25$104.3M$107.4MQ2 25$115.5M$142.3MQ3 25$264.0M$263.8MQ4 25$300.8M$306.0MQ1 26$393.4M$425.5MQ2 26
$0$200.0M$400.0MQ1 25Q3 25Q1 26

How Often Does Insmed Beat Earnings Estimates?

Insmed beat EPS estimates in 2 of its last 6 reported quarters, and has beaten 2 quarters in a row.

INSM quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q2 2026 Includes $99.8 million favorable change in fair value of contingent consideration liabilities in Q2 2026, compared to $59.0 million unfavorable change in Q2 2025 $-0.06 est. $-0.68 +91.30% $425.5M est. $393.4M +8.17%
Q1 2026 $-0.76 est. $-1.00 +23.93% $306.0M est. $300.8M +1.72%
Q4 2025 $-1.54 est. $-1.17 −31.92% $263.8M est. $264.0M −0.05%
Q3 2025 $-1.75 est. $-1.37 −28.02% $142.3M est. $115.5M +23.25%
Q2 2025 $-1.70 est. $-1.31 −29.59% $107.4M est. $104.3M +2.97%
Q1 2025 $-1.42 est. $-1.36 −4.36% $92.8M est. $92.1M +0.80%

Figures from SEC filings and company reports. Not investment advice.